Lacidipine

Lacidipine is indicated for the treatment of hypertension, either alone or in combination with other antihypertensive agents such as beta-blockers and diuretics.

Lacidipine inhibits the influx of calcium into smooth muscle cells by the competitive inhibition of voltage-dependent calcium 'L' channels. This action results in the inhibition of the effects triggered by the influx of calcium into the cells, such as the activation of the contractile proteins in smooth muscle.

Initially 2 mg as a single daily dose, preferably in the morning; increased after 3-4 weeks to 4 mg daily, then if necessary to 6 mg.

Cimetidine increases the concentration of Lacidipine. Lacidipine increases the concentration of Digoxin & Propranolol but Propranolol decreases the maximum concentration & AUC of Lacidipine.

Hypersensitivity to dihydropyridine derivatives. Cardiogenic shock, aortic stenosis, avoid within 1 month of myocardial infarction, impaired left ventricular function, pregnancy and breast-feeding.

Flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, aggravation of angina, mood disturbances, asthenia, polyuria, muscle cramps, skin rash (including pruritus and erythema).

Use in neonates: There are no data on safety or efficacy of Lacidipine in neonates.

Use in children: Treatment with Lacidipine have not been evaluated in Children.

Use in nursing mothers: Milk transfer studies showed that Lacidipine is excreted into breast milk and therefore, Lacidipine should not be used during lactation.

Use in pregnancy: Although no teratogenic effect of Lacidipine has been established in animals, there are no data on the safety of Lacidipine in human pregnancy; therefore it is contraindicated.

Cardiac conduction abnormalities, poor cardiac reserve, hepatic impairment, withdraw if ischemic pain occurs shortly after initiating treatment or if cardiogenic shock develops, avoid grapefruit juice (may affect metabolism).

Symptoms: Prolonged peripheral vasodilation associated with hypotension and tachycardia, bradycardia or prolonged AV conduction.

Management: Symptomatic and supportive treatment.

Calcium-channel blockers

Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.